Viridian Therapeutics Inc
Follow $VRDN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $VRDN by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is VRDN moving today?
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
VRDN overview
Related filings and maps
Congress activity in VRDN
No receipt-qualified Congressional disclosure is present for VRDN in the cached public ledger.
VRDN contract awards, year to date.
Public federal awards linked to this ticker.
VRDN lobbying filings, year to date.
Registered lobbying filings matched to Viridian Therapeutics Inc.